Physician

Vasileios John Assikis, M.D.

According to 2025 Medicare claims, Vasileios Assikis, M.D. (NPI: 1730147596) practices medical oncology in the Atlanta-Sandy Springs-Roswell, GA market, with the plurality of this provider's patient population coming from Coweta, GA. This provider's primary affiliated billing organization is PIEDMONT CANCER INSTITUTE PC (NPI: 1336180637; TIN: 581761689) and primary practice location at 30265-8303.

Assikis' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 830 traditional Medicare patients, billed 243,465 HCPCS/CPT codes, and received $5,706,432 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,558 prescription claims across 475 beneficiaries totaling $11,770,699 in drug costs, led by Xtandi (Enzalutamide). DME data shows 30 claims. Open Payments data shows 131 records totaling $637,952. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $2,207,652 to $5,706,432. Similarly, Part D prescription costs have moved sharply higher in recent years, from $3,405,663 to $11,770,699. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $13,516 to $1,380.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	889	165,014	$2,207,652
2016	852	158,559	$2,741,154
2017	829	154,790	$2,711,240
2018	831	127,014	$2,279,208
2019	856	160,997	$2,703,946
2020	853	155,311	$3,898,259
2021	795	231,881	$5,398,312
2022	776	184,252	$4,372,452
2023	858	268,649	$6,084,531
2024	830	243,465	$5,706,432

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	355	2,639	$3,405,663
2016	364	2,828	$4,089,235
2017	351	2,656	$4,507,500
2018	342	2,585	$4,962,903
2019	367	2,694	$5,766,607
2020	375	2,743	$5,830,277
2021	410	3,043	$9,350,705
2022	411	2,819	$8,363,617
2023	453	3,197	$9,449,546
2024	475	3,558	$11,770,699

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	48	365	$113,543
2016	N/R	433	$62,860
2017	N/R	177	$17,943
2018	22	118	$14,113
2019	N/R	66	$4,679
2020	N/R	95	$56,451
2021	N/R	136	$54,109
2022	N/R	113	$5,480
2023	N/R	93	$15,059
2024	N/R	30	$733

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	263	670	$86
96413	Administration of chemotherapy into vein, 1 hour or less	143	692	$85
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	382	694	$56
96372	Injection of drug or substance under skin or into muscle	129	365	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	440	1,242	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	144	4,320	$1,619,713
Erleada	Apalutamide	119	3,590	$1,594,515
Revlimid	Lenalidomide	85	2,303	$1,385,176
Nubeqa	Darolutamide	82	2,460	$987,883
Lupron Depot	Leuprolide Acetate	134	11,684	$807,814

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	15	$470
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	15	$263

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	53	$11,028	Gilead Sciences, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	78	$626,925	PFIZER INC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Vasileios John Assikis, M.D.?

Tedicare shows public-source Medicare data for Vasileios John Assikis, M.D. (NPI 1730147596), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Vasileios John Assikis, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Vasileios John Assikis, M.D.?

Vasileios John Assikis, M.D. is linked to PIEDMONT CANCER INSTITUTE PC (billing NPI 1336180637) in the available physician profile data.

Does Vasileios John Assikis, M.D. have Open Payments data?

Vasileios John Assikis, M.D. has 131 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.